ArticleClinical rheumatology2026
The role of double-negative T Cells in childhood-onset systemic lupus erythematosus and the impact of glucocorticoid therapy.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveDouble-negative T cells (DNTs) are significantly elevated in autoimmune diseases and are thought to play an important role in inflammation. The purpose of this study was to explore their role in childhood-onset systemic lupus erythematosus (cSLE).
methodsDNTs, as well as T and B cell subsets in peripheral blood, were detected by flow cytometry in 78 patients, including 34 cSLE. Clinical and laboratory data of cSLE patients were collected to analyze the correlation between DNTs and these indices, including demographics: proportion of female patients and mean age (± SD); Organ involvement: presence of lupus nephritis, neuropsychiatric manifestations, and pulmonary involvement; Hematologic parameters: leukopenia, anemia, and thrombocytopenia (WBC, Hb, and PLT counts); Autoantibody profiles: ANA, anti-dsDNA, and anti-Sm antibodies. The changes in DNT levels after glucocorticoid treatment were observed, and the effects of different doses of glucocorticoids on DNTs were analyzed.
resultsDNT levels were significantly increased in the peripheral blood of cSLE patients. DNTs were correlated with SLE disease activity, organ involvement, the production of autoantibodies, naive B cells, and plasmablasts. DNT levels increased after low-dose glucocorticoid treatment (9.12 ± 1.43 vs 14.24 ± 1.36, p < 0.01) but gradually decreased with increasing glucocorticoid doses (14.24 ± 1.36 vs 13.45 ± 1.51 vs 7.45 ± 1.01 vs 4.72 ± 1.20, p < 0.05). DNT levels significantly decreased from the fourth day of glucocorticoid pulse therapy.
conclusionDNT levels were positively correlated with disease activity in cSLE patients, and the effect of glucocorticoid dose on DNT levels varied. Key Points • DNT cells are significantly elevated in cSLE patients and correlate with disease activity, organ involvement, and autoantibody profiles. Low-dose glucocorticoids transiently increase circulating DNT levels, while higher doses progressively reduce DNT frequencies. DNT levels positively correlate with B-cell subsets, suggesting a potential role in autoantibody production in pediatric SLE. • Dynamic changes in DNTs may be influenced by glucocorticoid treatment.
Indexed as
Identifiers
41697499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.